Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 2/2013

01-04-2013

A Cutting Edge Overview: Psoriatic Disease

Author: Siba P. Raychaudhuri

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2013

Login to get access

Abstract

Psoriasis is a lifelong skin disease, affecting about 2% of the global population. Generalized involvement of the body (erythroderma), extensive pustular lesions, and an associated arthritis known as psoriatic arthritis (PsA) are severe complications of psoriasis. Genetic, immunologic, and environmental factors contribute to its pathogenesis. A complete understanding of the pathogenesis of psoriasis and psoriatic arthritis is lacking. Cytokines, chemokines, adhesion molecules, growth factors like NGF, neuropeptides, and T cell receptors all act in an integrated way to evolve into unique inflammatory and proliferative processes typical of psoriasis and PsA. Management of psoriasis requires exemplary skin care along with careful monitoring of arrays of comorbidities which includes arthritis and coronary artery disease. In many ways, psoriasis can be considered a model autoimmune disease. This statement itself is ironic considering that it was not recognized as immune mediated until relatively recently. Fortunately, the immunobiology has made enormous strides and there are now excellent therapeutic options for patients. In this thematic review, we have attempted to provide summaries of not only basic science and clinical research, but also an overview of future research directions.
Literature
1.
go back to reference Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866–873PubMedCrossRef Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866–873PubMedCrossRef
2.
go back to reference Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210–212PubMed Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210–212PubMed
3.
go back to reference Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef
4.
go back to reference Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159:895–802PubMedCrossRef Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159:895–802PubMedCrossRef
5.
go back to reference Stuart PE, Nair RP, Ellinghaus E et al (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42:1000–1004PubMedCrossRef Stuart PE, Nair RP, Ellinghaus E et al (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42:1000–1004PubMedCrossRef
6.
go back to reference Nickoloff BJ, Schröder JM, von den Driesch P et al (2000) Is psoriasis a T-cell disease? Exp Dermatol 9:359–375PubMedCrossRef Nickoloff BJ, Schröder JM, von den Driesch P et al (2000) Is psoriasis a T-cell disease? Exp Dermatol 9:359–375PubMedCrossRef
7.
go back to reference Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–J321PubMedCrossRef Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–J321PubMedCrossRef
8.
go back to reference Nickoloff BJ (2006) Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12:102–106PubMedCrossRef Nickoloff BJ (2006) Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12:102–106PubMedCrossRef
9.
go back to reference Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271PubMedCrossRef Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271PubMedCrossRef
10.
go back to reference Hertle MD, Kubler MD, Leigh IM, Watt FM (1992) Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 89:1892–1901PubMedCrossRef Hertle MD, Kubler MD, Leigh IM, Watt FM (1992) Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 89:1892–1901PubMedCrossRef
11.
go back to reference Sa SM, Valdez PA, Wu J et al (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178:2229–2240PubMed Sa SM, Valdez PA, Wu J et al (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178:2229–2240PubMed
12.
go back to reference Wolk K, Witte E, Warszawska K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570–3581PubMedCrossRef Wolk K, Witte E, Warszawska K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570–3581PubMedCrossRef
13.
go back to reference Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) L-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359:419–429PubMedCrossRef Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) L-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359:419–429PubMedCrossRef
14.
go back to reference Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961–971PubMedCrossRef Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961–971PubMedCrossRef
15.
go back to reference Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB (1999) Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 79:9–11PubMedCrossRef Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB (1999) Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 79:9–11PubMedCrossRef
16.
go back to reference Romanowska M, al Yacoub N, Seidel H et al (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128:110–124PubMedCrossRef Romanowska M, al Yacoub N, Seidel H et al (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128:110–124PubMedCrossRef
17.
go back to reference Széles L, Töröcsik D, Nagy L (2007) PPAR gamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771:1014–1030PubMedCrossRef Széles L, Töröcsik D, Nagy L (2007) PPAR gamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771:1014–1030PubMedCrossRef
18.
go back to reference al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940–1949PubMedCrossRef al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940–1949PubMedCrossRef
19.
go back to reference Sagoo GS, Tazi-Ahnini R, Barker JW et al (2004) Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 122:1401–1405PubMedCrossRef Sagoo GS, Tazi-Ahnini R, Barker JW et al (2004) Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 122:1401–1405PubMedCrossRef
20.
go back to reference Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D (1998) Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 110:958–960PubMedCrossRef Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D (1998) Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 110:958–960PubMedCrossRef
21.
go back to reference Veal CD, Clough RL, Barber RC et al (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38:7–13PubMedCrossRef Veal CD, Clough RL, Barber RC et al (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38:7–13PubMedCrossRef
22.
go back to reference Capon F, Semprini S, Chimenti S et al (2001) Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116:728–730PubMedCrossRef Capon F, Semprini S, Chimenti S et al (2001) Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116:728–730PubMedCrossRef
23.
go back to reference Nair RP, Duffin KC, Helms C et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199–204PubMedCrossRef Nair RP, Duffin KC, Helms C et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199–204PubMedCrossRef
24.
go back to reference Zhang XJ, Huang W, Yang S et al (2009) Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41:205–210PubMedCrossRef Zhang XJ, Huang W, Yang S et al (2009) Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41:205–210PubMedCrossRef
25.
go back to reference Campalani E, Allen MH, Fairhurst D et al (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154:345–352PubMedCrossRef Campalani E, Allen MH, Fairhurst D et al (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154:345–352PubMedCrossRef
26.
go back to reference Gottlieb AB, Lebwohl M, Shirin S et al (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43:595–504PubMedCrossRef Gottlieb AB, Lebwohl M, Shirin S et al (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43:595–504PubMedCrossRef
27.
go back to reference Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878–1887PubMedCrossRef Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878–1887PubMedCrossRef
28.
go back to reference Eyerich S, Eyerich K, Pennino D et al (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119:3573–3585PubMed Eyerich S, Eyerich K, Pennino D et al (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119:3573–3585PubMed
29.
go back to reference Caruso R, Botti E, Sarra M et al (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013–1015PubMedCrossRef Caruso R, Botti E, Sarra M et al (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013–1015PubMedCrossRef
30.
go back to reference Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339–1350PubMedCrossRef Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339–1350PubMedCrossRef
31.
go back to reference Shibata S, Tada Y, Kanda N et al (2010) Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 130:1034–1039PubMedCrossRef Shibata S, Tada Y, Kanda N et al (2010) Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 130:1034–1039PubMedCrossRef
32.
go back to reference Lowes MA, Chamian F, Abello MV et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci 102:19057–19062PubMedCrossRef Lowes MA, Chamian F, Abello MV et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci 102:19057–19062PubMedCrossRef
33.
go back to reference Wang H, Peters T, Kess D et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105–2114PubMedCrossRef Wang H, Peters T, Kess D et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105–2114PubMedCrossRef
34.
go back to reference Braverman IM, Yen A (1977) Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 68:53–60PubMedCrossRef Braverman IM, Yen A (1977) Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 68:53–60PubMedCrossRef
35.
go back to reference Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ (1999) Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 42:1481–1484PubMedCrossRef Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ (1999) Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 42:1481–1484PubMedCrossRef
36.
go back to reference Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236PubMedCrossRef Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236PubMedCrossRef
37.
go back to reference Libby P, Paul M, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143PubMedCrossRef Libby P, Paul M, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143PubMedCrossRef
38.
go back to reference Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251–266PubMedCrossRef Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251–266PubMedCrossRef
39.
go back to reference Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331–334PubMedCrossRef Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331–334PubMedCrossRef
40.
go back to reference Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736–1744PubMedCrossRef Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736–1744PubMedCrossRef
41.
go back to reference Hershko AY, Naparstek Y (2006) Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 5:230–233PubMedCrossRef Hershko AY, Naparstek Y (2006) Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 5:230–233PubMedCrossRef
42.
go back to reference Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178–J206PubMedCrossRef Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178–J206PubMedCrossRef
43.
go back to reference Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:A251–A258PubMedCrossRef Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:A251–A258PubMedCrossRef
44.
go back to reference Martin PI, Malizia AI, Rewald E (2008) A propos time and autoimmunity. Clin Rev Allergy Immunol 34:380–384PubMedCrossRef Martin PI, Malizia AI, Rewald E (2008) A propos time and autoimmunity. Clin Rev Allergy Immunol 34:380–384PubMedCrossRef
45.
go back to reference Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34:J247–J257PubMedCrossRef Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34:J247–J257PubMedCrossRef
46.
go back to reference Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276–J286PubMedCrossRef Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276–J286PubMedCrossRef
47.
48.
go back to reference Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163–J167PubMedCrossRef Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163–J167PubMedCrossRef
49.
go back to reference Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:A267–A270PubMedCrossRef Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:A267–A270PubMedCrossRef
50.
go back to reference Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168–J177PubMedCrossRef Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168–J177PubMedCrossRef
51.
go back to reference Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325–330PubMedCrossRef Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325–330PubMedCrossRef
53.
go back to reference Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–A292PubMedCrossRef Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–A292PubMedCrossRef
54.
go back to reference Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:A293–A298PubMedCrossRef Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:A293–A298PubMedCrossRef
55.
go back to reference Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:A325–A329PubMedCrossRef Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:A325–A329PubMedCrossRef
56.
go back to reference Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:A400–A405PubMedCrossRef Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:A400–A405PubMedCrossRef
57.
go back to reference Round JL, O’Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220–J225PubMedCrossRef Round JL, O’Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220–J225PubMedCrossRef
58.
go back to reference Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335–A341PubMedCrossRef Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335–A341PubMedCrossRef
59.
go back to reference Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259–A266PubMedCrossRef Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259–A266PubMedCrossRef
60.
go back to reference Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:A372–A378PubMedCrossRef Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:A372–A378PubMedCrossRef
61.
go back to reference Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9:A379–A382PubMedCrossRef Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9:A379–A382PubMedCrossRef
62.
go back to reference Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226–J233PubMedCrossRef Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226–J233PubMedCrossRef
63.
go back to reference Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:J287–J299PubMedCrossRef Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:J287–J299PubMedCrossRef
64.
go back to reference Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287PubMedCrossRef Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287PubMedCrossRef
65.
go back to reference Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRef Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRef
66.
go back to reference Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207–J219PubMedCrossRef Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207–J219PubMedCrossRef
67.
go back to reference Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234–J246PubMedCrossRef Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234–J246PubMedCrossRef
68.
go back to reference Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–J265PubMedCrossRef Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–J265PubMedCrossRef
69.
go back to reference Langham S, Langham J, Goertz HP, Ratcliffe M (2011) Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systemic and critical review. BMC Med Res Methodol 11:32PubMedCrossRef Langham S, Langham J, Goertz HP, Ratcliffe M (2011) Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systemic and critical review. BMC Med Res Methodol 11:32PubMedCrossRef
70.
go back to reference Slutsky JB, Clark RA, Remedios AA, Klein PA (2010) An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 9:1258–1264PubMed Slutsky JB, Clark RA, Remedios AA, Klein PA (2010) An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 9:1258–1264PubMed
71.
go back to reference O’Neill JL, Feldman SR (2010) Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 46:351–360 O’Neill JL, Feldman SR (2010) Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 46:351–360
72.
go back to reference Seminara NM, Gelfand JM (2010) Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 29:16–19PubMedCrossRef Seminara NM, Gelfand JM (2010) Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 29:16–19PubMedCrossRef
73.
go back to reference Baraliakos X, Braun J (2010) Anti-TNF-alpha therapy with infliximab in spondyloarthritides. Expert Rev Clin Immunol 6:9–19PubMedCrossRef Baraliakos X, Braun J (2010) Anti-TNF-alpha therapy with infliximab in spondyloarthritides. Expert Rev Clin Immunol 6:9–19PubMedCrossRef
74.
go back to reference Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273–288PubMedCrossRef Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273–288PubMedCrossRef
75.
go back to reference Piconese S, Costanza M, Tripodo C, Sangaletti S, Musio S, Pittoni P, Poilani PL, Burocchi A, Passafaro AL, Gorzanelli A, Vitali C, Chiodoni C, Barnaba V, Pedotti R, Colombo MP (2011) The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun 37:300–310PubMedCrossRef Piconese S, Costanza M, Tripodo C, Sangaletti S, Musio S, Pittoni P, Poilani PL, Burocchi A, Passafaro AL, Gorzanelli A, Vitali C, Chiodoni C, Barnaba V, Pedotti R, Colombo MP (2011) The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun 37:300–310PubMedCrossRef
76.
go back to reference Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W, Nussenblatt RB, Philip McCoy J Jr (2011) MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun 37:319–327PubMedCrossRef Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W, Nussenblatt RB, Philip McCoy J Jr (2011) MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun 37:319–327PubMedCrossRef
77.
go back to reference Kaminski S, Hermann-Kleiter N, Meisel M, Thuille N, Cronin S, Hara H, Fresser F, Penninger JM, Baier G (2011) Coronin 1A is an essential regulator of the TGFβ receptor/SMAD3 signaling pathway in Th17 CD4(+) T cells. J Autoimmun 37:198–208PubMedCrossRef Kaminski S, Hermann-Kleiter N, Meisel M, Thuille N, Cronin S, Hara H, Fresser F, Penninger JM, Baier G (2011) Coronin 1A is an essential regulator of the TGFβ receptor/SMAD3 signaling pathway in Th17 CD4(+) T cells. J Autoimmun 37:198–208PubMedCrossRef
78.
go back to reference Wang YL, Chou FC, Chen SJ, Lin SH, Chang DM, Sytwu HK (2011) Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases—an unrevealed role in downregulation of Th17 cells. J Autoimmun 37:160–170PubMedCrossRef Wang YL, Chou FC, Chen SJ, Lin SH, Chang DM, Sytwu HK (2011) Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases—an unrevealed role in downregulation of Th17 cells. J Autoimmun 37:160–170PubMedCrossRef
79.
go back to reference Baugh M, Black D, Westwood P, Kinghorn E et al (2011) Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 36:201–209PubMedCrossRef Baugh M, Black D, Westwood P, Kinghorn E et al (2011) Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 36:201–209PubMedCrossRef
80.
go back to reference Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65–75PubMedCrossRef Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65–75PubMedCrossRef
81.
go back to reference Oo YH, Adams DH (2010) The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 34:45–54PubMedCrossRef Oo YH, Adams DH (2010) The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 34:45–54PubMedCrossRef
82.
go back to reference Reich A, Szepietowski JC (2011) Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 12:313–320PubMedCrossRef Reich A, Szepietowski JC (2011) Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 12:313–320PubMedCrossRef
Metadata
Title
A Cutting Edge Overview: Psoriatic Disease
Author
Siba P. Raychaudhuri
Publication date
01-04-2013
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2013
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-012-8309-z

Other articles of this Issue 2/2013

Clinical Reviews in Allergy & Immunology 2/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.